Greenberg Traurig has represented Japan’s Ono Pharmaceutical Co on its $2.4 billion acquisition of U.S.-based cancer drugmaker Deciphera, which was advised by Goodwin Procter.
According to Reuters, the deal will help Ono expand its oncology portfolio and presence in the United States and Europe.
Deciphera's oral drug Qinlock, which treats a type of gastrointestinal cancer, received the U.S. Food and Drug Administration's full approval in 2020. The company also plans to seek a nod for vimseltinib, its experimental medicine to treat tenosynovial giant cell tumour, a type of tumour found in some joints, Reuters added.
The Greenberg Traurig team was co-led by shareholders Chia-Feng Lu and Michael D. Helsel, while the Goodwin team was helmed by global M&A head Stuart Cable and partners Richard Hoffman, Lisa Haddad, and James Ding.
